Compare iShares Global Clean Energy ETF (ICLN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Sanofi SA — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.27B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 41.9× iShares Global Clean Energy ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Sanofi SA for 94 Days on average.
| ICLN | SNY | |
|---|---|---|
Market Cap | $2.27B | $95.18B |
Volume | 6,845,064 | 2,995,646 |
52-Week High | $23.75 | $52.34 |
52-Week Low | $15.78 | $39.51 |
Typical Hold Time | 87 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.12, down 1.1% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF faces volatility in clean energy markets, with recent comparisons highlighting deeper drawdowns versus traditional energy ETFs. News indicates global renewable energy acceleration due to geopolitical tensions, potentially benefiting ICLN's long-term theme.
The outlook remains cautious near-term due to technical weakness and competitive fee pressures, but long-term growth prospects are supported by energy transition trends. Key risks include high volatility, expense ratios, and fossil fuel competition. Analyst sentiment is mixed, weighing near-term headwinds against structural shifts.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
